More Research

Allergy Therapeutics

Record revenues demonstrate resilience of operations
Update | 02 Mar 2021

Allergy Therapeutics

Robust growth, pipeline progress, and cash position
Update | 13 Jan 2021

Allergy Therapeutics

Imperial peanut allergy biomarker study underway
Lighthouse | 05 Jan 2021

Allergy Therapeutics

Innovative G309 exploratory grass trial starts
Lighthouse | 26 Oct 2020

Allergy Therapeutics

Strong performances against strategic goals
Initiation | 23 Sep 2020

Return to Allergy Therapeutics
© 2019-21 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).